258 related articles for article (PubMed ID: 33754215)
21. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
Sørensen AL; Hansen RL; Jørgensen PH
Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
[TBL] [Abstract][Full Text] [Related]
22. Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy.
Yonezawa N; Murakami H; Kato S; Takeuchi A; Tsuchiya H
Eur Spine J; 2017 May; 26(Suppl 1):236-242. PubMed ID: 28396950
[TBL] [Abstract][Full Text] [Related]
23. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
[TBL] [Abstract][Full Text] [Related]
24. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
Palmerini E; Seeger LL; Gambarotti M; Righi A; Reichardt P; Bukata S; Blay JY; Dai T; Jandial D; Picci P
BMC Cancer; 2021 Jan; 21(1):89. PubMed ID: 33482769
[TBL] [Abstract][Full Text] [Related]
25. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
Ueda T; Morioka H; Nishida Y; Kakunaga S; Tsuchiya H; Matsumoto Y; Asami Y; Inoue T; Yoneda T
Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
[TBL] [Abstract][Full Text] [Related]
26. Current management of giant-cell tumor of bone in the denosumab era.
Nagano A; Urakawa H; Tanaka K; Ozaki T
Jpn J Clin Oncol; 2022 May; 52(5):411-416. PubMed ID: 35199172
[TBL] [Abstract][Full Text] [Related]
27. The multidisciplinary management of giant cell tumor of bone.
Ng VY; Davidson DJ; Kim EY; Pollack SM; Conrad Iii EU; Jones RL
Expert Rev Anticancer Ther; 2014 Jul; 14(7):783-90. PubMed ID: 24666240
[TBL] [Abstract][Full Text] [Related]
28. A High-grade Sarcoma Arising in a Patient With Recurrent Benign Giant Cell Tumor of the Proximal Tibia While Receiving Treatment With Denosumab.
Aponte-Tinao LA; Piuzzi NS; Roitman P; Farfalli GL
Clin Orthop Relat Res; 2015 Sep; 473(9):3050-5. PubMed ID: 25758379
[TBL] [Abstract][Full Text] [Related]
29. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab.
Chinder PS; Hindiskere S; Doddarangappa S; Pal U
Clin Orthop Surg; 2019 Sep; 11(3):352-360. PubMed ID: 31475058
[TBL] [Abstract][Full Text] [Related]
31. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
Reddy K; Ramirez L; Kukreja K; Venkatramani R
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e215-e218. PubMed ID: 31714440
[TBL] [Abstract][Full Text] [Related]
32. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
Shibuya I; Takami M; Miyamoto A; Karakawa A; Dezawa A; Nakamura S; Kamijo R
Pathol Oncol Res; 2019 Jan; 25(1):409-419. PubMed ID: 29159783
[TBL] [Abstract][Full Text] [Related]
33. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
Chawla S; Blay JY; Rutkowski P; Le Cesne A; Reichardt P; Gelderblom H; Grimer RJ; Choy E; Skubitz K; Seeger L; Schuetze SM; Henshaw R; Dai T; Jandial D; Palmerini E
Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
[TBL] [Abstract][Full Text] [Related]
34. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
[TBL] [Abstract][Full Text] [Related]
35. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
Rutkowski P; Ferrari S; Grimer RJ; Stalley PD; Dijkstra SP; Pienkowski A; Vaz G; Wunder JS; Seeger LL; Feng A; Roberts ZJ; Bach BA
Ann Surg Oncol; 2015 Sep; 22(9):2860-8. PubMed ID: 26033180
[TBL] [Abstract][Full Text] [Related]
36. Denosumab treatment for progressive skull base giant cell tumor of bone in a 14 year old female - a case report and literature review.
Bardakhchyan S; Kager L; Danielyan S; Avagyan A; Karamyan N; Vardevanyan H; Mkhitaryan S; Papyan R; Zohrabyan D; Safaryan L; Sargsyan L; Harutyunyan L; Hakobyan L; Iskanyan S; Tamamyan G
Ital J Pediatr; 2017 Mar; 43(1):32. PubMed ID: 28356124
[TBL] [Abstract][Full Text] [Related]
37. Giant Cell Lesions of the Maxillofacial Skeleton Express RANKL by RNA In Situ Hybridization Regardless of Histologic Pattern.
Stagner AM; Sajed DP; Nielsen GP; Ebb DH; Faquin WC; Chebib I; Rivera MN; Ting DT; Resnick CM; Peacock ZS; Kaban LB; Deshpande V
Am J Surg Pathol; 2019 Jun; 43(6):819-826. PubMed ID: 30998511
[TBL] [Abstract][Full Text] [Related]
38. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
Yamamoto H; Ishihara S; Toda Y; Oda Y
Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
[TBL] [Abstract][Full Text] [Related]
39. Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection?
Sambri A; Medellin MR; Errani C; Campanacci L; Fujiwara T; Donati D; Parry M; Grimer R
J Orthop Sci; 2020 May; 25(3):513-519. PubMed ID: 31155442
[TBL] [Abstract][Full Text] [Related]
40. Recommencement of Denosumab for Unresectable Giant Cell Tumor of the Cervical Spine: A Case Report.
Law GW; Yeo NEM; Howe TS; Tan YZ; Tan SB; Siddiqui MMA
Spine (Phila Pa 1976); 2018 May; 43(9):E551-E556. PubMed ID: 29016442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]